|
NIH findings offer additional safeguard for children of mothers untreated during pregnancy
2-Mar-2011 - Pregnant women who are unaware that they have HIV miss the chance for drug treatment that can
benefit not only their own health, but could also prevent them from transmitting the virus to their infants. When HIV is not
diagnosed until women go into labor, their infants are usually treated soon after birth with the anti
HIV drug zidovudine (ZDV), to prevent the infants from becoming infected with the virus.
Now, a National Institutes of Health study has found that adding one or two drugs to the standard ZDV treatment
can reduce the chances by more than 50 percent that an infant will develop an HIV infection.
The study results were presented on, March 2, at the 18th Conference on Retroviruses and Opportunistic
Infections, in Boston. The study was conducted at research hospitals in Brazil, South Africa, Argentina, and the United States,
under contract to the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Additional funding was provided by the NIH's National Institute of Allergy and Infectious Diseases.
An estimated one fifth of people in the United States who have HIV are unaware that they harbor the virus.
From 100 to 200 infants are born with HIV in the United States each year, many to women who either were not tested in early
pregnancy or who did not receive treatment during pregnancy. Internationally, estimates of HIV testing vary, with only
21 percent of pregnant women in low and middle income countries having been tested for HIV during pregnancy.
"To reduce mother-to-child HIV transmission, it's best to begin antiretroviral treatment during pregnancy," said
Heather Watts, M.D., a medical officer in NICHD's Pediatric, Adolescent and Maternal AIDS Branch, and an author of the
study. "However, when treatment during pregnancy isn't possible, our results show that adding one or two
drugs to the current regimen provides another important means to reduce the chance for mother-to-child HIV transmission."
At the 19 participating research sites, the NICHD/ HIV Prevention Trials Network 040 study evaluated 1,684 infants born to
women whose HIV infections were not diagnosed until they were in labor. The infants were randomly assigned to three groups: those
receiving the standard 6 weeks of therapy with ZDV, those receiving 6 weeks of ZDV plus 3 doses of nevirapine (NVP) during the
first week of life, and those receiving 6 weeks of ZDV plus two weeks of lamivudine (3TC) and nelfinavir (NFV). The study
results showed that treatment with the two and three drug regimens reduced HIV transmission by more than 50 percent.
ZDV, ZDV+NVP, ZDV+3TC+NFV
Proportion with HIV infection at 3 months
4.9 percent, 2.2 percent, 2.5 percent
"Our results showed conclusively that the two and three drug regimens are superior to the standard treatment with
zidovudine," said study chair Karin Nielsen-Saines, M.D., clinical professor of pediatrics in the Division of Infectious
Diseases at the David Geffen School of Medicine at the University of California at Los Angeles.
###
Other authors of the study were Valdilea Gonçalves Veloso, Fiocruz Institute, Rio de Janeiro; Yvonne J. Bryson, David Geffen
School of Medicine; Esau C. Joao, Servants of the State Hospital, Rio de Janeiro;, Jose Henrique Pilotto, General Hospital of Nova
Iguacu, Nova Iguacu, Brazil; Glenda Gray, Chris Hani Baragwanath Hospital, Johannesburg; Gerhard Theron, Tygerberg Hospital,
Capetown, South Africa; James Bethel, Westat, Inc., Rockville, Md.; and Lynne Mofenson, NICHD.
The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and
population issues; and medical rehabilitation. For more information, visit the Institute's Web site
at http://www.nichd.nih.gov/ .
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component
of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical,
and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.
For more information about NIH and its programs, visit http://www.nih.gov .
Contact: Robert Bock
bockr@mail.nih.gov
301-496-5134
NIH/National Institute of Child Health and Human Development
Source: EurekAlert!
http://www.eurekalert.org/pub_releases/2011-03/nioc-ndr030111.php
|
